JP2017061471A5 - - Google Patents

Download PDF

Info

Publication number
JP2017061471A5
JP2017061471A5 JP2016204089A JP2016204089A JP2017061471A5 JP 2017061471 A5 JP2017061471 A5 JP 2017061471A5 JP 2016204089 A JP2016204089 A JP 2016204089A JP 2016204089 A JP2016204089 A JP 2016204089A JP 2017061471 A5 JP2017061471 A5 JP 2017061471A5
Authority
JP
Japan
Prior art keywords
multimer
component
protein
cell
components
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016204089A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017061471A (ja
JP6717725B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017061471A publication Critical patent/JP2017061471A/ja
Publication of JP2017061471A5 publication Critical patent/JP2017061471A5/ja
Application granted granted Critical
Publication of JP6717725B2 publication Critical patent/JP6717725B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016204089A 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体 Active JP6717725B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161484052P 2011-05-09 2011-05-09
US61/484,052 2011-05-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014510413A Division JP2014517690A (ja) 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019211946A Division JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体

Publications (3)

Publication Number Publication Date
JP2017061471A JP2017061471A (ja) 2017-03-30
JP2017061471A5 true JP2017061471A5 (enExample) 2017-10-12
JP6717725B2 JP6717725B2 (ja) 2020-07-01

Family

ID=47139949

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2014510413A Pending JP2014517690A (ja) 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体
JP2016204089A Active JP6717725B2 (ja) 2011-05-09 2016-10-18 遺伝子操作した成長因子変異体
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2014510413A Pending JP2014517690A (ja) 2011-05-09 2012-05-08 遺伝子操作した成長因子変異体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019211946A Pending JP2020039359A (ja) 2011-05-09 2019-11-25 遺伝子操作した成長因子変異体
JP2021193554A Pending JP2022031824A (ja) 2011-05-09 2021-11-29 遺伝子操作した成長因子変異体
JP2024006988A Pending JP2024056702A (ja) 2011-05-09 2024-01-19 遺伝子操作した成長因子変異体

Country Status (8)

Country Link
US (3) US20140065113A1 (enExample)
EP (1) EP2707021B1 (enExample)
JP (5) JP2014517690A (enExample)
CN (2) CN103930439A (enExample)
AU (1) AU2012253652B2 (enExample)
CA (1) CA2835453A1 (enExample)
IL (1) IL229316B (enExample)
WO (1) WO2012154759A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012126013A2 (en) 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants
KR20210082547A (ko) * 2013-02-20 2021-07-05 미네르바 바이오테크놀로지 코포레이션 Ｎｍｅ 저해제 및 ｎｍｅ 저해제의 사용 방법
WO2016061396A1 (en) * 2014-10-16 2016-04-21 Counsyl, Inc. Variant caller
WO2021263227A2 (en) 2020-06-26 2021-12-30 Minerva Biotechnologies Corporation Anti-nme antibody and method of treating cancer or cancer metastasis
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
WO2023201234A2 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation Anti-variable muc1* antibodies and uses thereof
CN117736272B (zh) * 2024-02-19 2024-04-30 四川省医学科学院·四川省人民医院 一种具有促成骨功能的生物活性多肽

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE206129T1 (de) * 1989-10-18 2001-10-15 Us Health Herstellung und verwendung des menschlichen nm23- h2-proteins und dagegen gerichtete antikörper
US5958671A (en) * 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US20050112607A1 (en) * 1999-01-23 2005-05-26 Bamdad Cynthia C. Rapid and sensitive detection of protein aggregation
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
AU782496B2 (en) * 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
US20020169290A1 (en) * 2000-11-02 2002-11-14 Claus Bornaes New multimeric interferon beta polypeptides
EP1334127A1 (en) * 2000-11-02 2003-08-13 Maxygen Aps Single-chain multimeric polypeptides
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
CA2441986A1 (en) * 2001-03-27 2002-10-03 Massachusetts Institute Of Technology Methods and products related to fgf dimerization
EP1353182A3 (en) * 2002-04-12 2004-02-04 Smithkline Beecham Corporation Method of predicting cell-based assay results using binding profiles
EP1553963A4 (en) * 2002-09-24 2006-05-03 Burnham Inst NEW MEANS FOR MODULATING EPH RECEPTOR ACTIVITY
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
US20050054752A1 (en) * 2003-09-08 2005-03-10 O'brien John P. Peptide-based diblock and triblock dispersants and diblock polymers
CA2553187A1 (en) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Heterodimeric follicle stimulating hormone-fc (fsh-fc) fusion proteins for the treatment of infertility
EP2418223A3 (en) * 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
CN101652469B (zh) * 2006-12-06 2014-04-16 米纳瓦生物技术公司 用于鉴定和操作细胞的方法
WO2010003118A1 (en) * 2008-07-02 2010-01-07 Trubion Pharmaceuticals, Inc. Tgf-b antagonist multi-target binding proteins
KR20160017117A (ko) * 2008-10-09 2016-02-15 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
EP4043552A1 (en) * 2009-06-11 2022-08-17 Minerva Biotechnologies Corporation Methods for culturing stem and progenitor cells
WO2011103049A2 (en) * 2010-02-16 2011-08-25 Immune Disease Institute, Inc. Method for screening receptors/ligands interactions
WO2012126013A2 (en) * 2011-03-17 2012-09-20 Minerva Biotechnologies Corporation Method for making pluripotent stem cells
EP2707021B1 (en) * 2011-05-09 2024-02-21 Minerva Biotechnologies Corporation Genetically engineered growth factor variants

Similar Documents

Publication Publication Date Title
JP2017061471A5 (enExample)
TWI856979B (zh) 三特異性抗ｃｄ３８、抗ｃｄ２８和抗ｃｄ３結合蛋白和用於治療病毒感染的使用方法
JP7227290B2 (ja) キメラ抗原受容体、組成物及び方法
US20240279303A1 (en) Tissue-specific wnt signal enhancing molecules and uses thereof
TWI878330B (zh) 特異性結合mage-a的抗原結合蛋白
TWI860971B (zh) 用於結合ａｘｌ之嵌合抗原受體、經分離之重組ｔ細胞、載體及在體外活化ｔ細胞的方法
JP2014517690A5 (enExample)
CN110922468B (zh) 用于治疗或预防疾病的因子1蛋白、因子2蛋白及其抑制剂
JP2018512856A5 (enExample)
JP2018519296A5 (enExample)
JP2017525354A5 (enExample)
JP2013531470A5 (enExample)
JP2020510658A (ja) 操作されたヘテロ二量体タンパク質
CN107406509A (zh) 包含结合至5t4和cd3的三个结合结构域的融合蛋白
CN107223135A (zh) 用于治疗hbv感染和相关病症的三特异性结合分子
JP2014519830A5 (enExample)
JP2016516049A5 (enExample)
CN101360758A (zh) 用于登革病毒的4种血清型和其他黄病毒的预防和/或治疗性治疗的方法和蛋白质
JP2015518479A5 (enExample)
CN107709355A (zh) 单链cd40受体激动剂蛋白
Zhang et al. Functional antibody CDR3 fusion proteins with enhanced pharmacological properties
US20220218752A1 (en) Lockr-mediated recruitment of car t cells
JP6717725B2 (ja) 遺伝子操作した成長因子変異体
JP2018538356A5 (enExample)
JP2018530331A5 (enExample)